Teva launches authorized generic of Epiduo Forte Gel in USA

1 December 2021

The US affiliate of Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) today announced the launch of an authorized USA.

Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used for the treatment of acne vulgaris.

“The launch of our first-to-market authorized generic version of Epiduo Forte Gel in the US provides patients with another important treatment option,” said Christine Baeder, senior vice president, chief operating officer US Generics, Teva USA, adding: “Continuing to advance and launch much-needed generic drugs is critical to ensuring access to quality medicines to everyone who needs them."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK